ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > Protein > Glycoprotein E (VZV) > GLE-V52H3

Varicella zoster virus (strain Oka vaccine) Envelope Glycoprotein E (gE), His Tag (MALS verified)

  • Synonym
    gE
  • Source
    Varicella zoster virus (strain Oka vaccine) Envelope Glycoprotein E (gE), His Tag(GLE-V52H3) is expressed from human 293 cells (HEK293). It contains AA Ser 31 - Ala 546 (Accession # Q9J3M8-1).
    Predicted N-terminus: Ser 31
  • Molecular Characterization
    Glycoprotein E (VZV) Structure

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 60.2 kDa. The protein migrates as 54-69 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >90% as determined by SDS-PAGE.

    >90% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
Glycoprotein E (VZV) SDS-PAGE

Varicella zoster virus (strain Oka vaccine) Envelope Glycoprotein E (gE), His Tag on SDS-PAGE under non-reducing (NR) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

SEC-MALS
Glycoprotein E (VZV) MALS images

The purity of Varicella zoster virus (strain Oka vaccine) Envelope Glycoprotein E (gE), His Tag (Cat. No. GLE-V52H3) is more than 90% and the molecular weight of this protein is around 60-85 kDa verified by SEC-MALS.

Bioactivity-ELISA
 Glycoprotein E (VZV) ELISA

Immobilized Varicella zoster virus (strain Oka vaccine) Envelope Glycoprotein E (gE), His Tag (Cat. No. GLE-V52H3) at 1 μg/mL (100 μL/well) can bind Anti-Glycoprotein E (VZV) Antibody, Human IgG1 (4G2) with a linear range of 0.02-1 ng/mL (QC tested).

Bioactivity-SPR
 Glycoprotein E (VZV) SPR

Anti-Glycoprotein E (VZV) Antibody, Human IgG1 (4G2) captured on Protein A Chip can bind Varicella zoster virus (strain Oka vaccine) Envelope Glycoprotein E (gE), His Tag (Cat. No. GLE-V52H3) with an affinity constant of 4.81 nM as determined in SPR assay (Biacore 8K) (Routinely tested).

  • Background
    Varicella-zoster virus (VZV) is a neurotropic virus belonging to the Herpesviridae family. Primary VZV infection causes chickenpox and is followed by a life-long latent infection established mainly in the cranial and dorsal root ganglia. Reactivation of the virus is often associated with shingles (herpes zoster).

    Glycoprotein E (gE) is one of the known glycoproteins (gB, gC, gE, gH, gI, gK, gI) of VZV that is most abundantly expressed on the surface of virus and infected cells, playing an important role in viral replication and cell-to-cell spread. The strongly immunogenic gE can provide strong IgG signal in body fluid, which makes it ideal to be developed as an antigen for analysis of IgG antibodies. gE also demonstrates high potency as a vaccine immunogen and is formulated as the single viral envelope protein that constitutes the GSK VZV recombinant subunit vaccine Shingrix®.

  • Clinical and Translational Updates

コメント (0)


ETD of in-stock products: 4 business days

価格(JPY) : 64,400

価格(JPY) : 554,400

人気商品のおすすめ
抗His抗体

価格(JPY) : 67,200

価格(JPY) : 442,400

コンジュゲート HRP Anti-His 抗体

価格(JPY) : 70,000

価格(JPY) : 470,400

プロモーション&展示



医薬品開発状況

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:1 Details
  • Latest Research Phase:Phase 1 Clinical

データシート&ドキュメンテーション

DMF請求
DMF (Drug Master File)

関連製品一覧

新製品

お問い合わせ&コメント

This web search service is supported by Google Inc.

totopphone